HP Improves Sleep and Overall Survival Rate in Maintenance Hemodialysis Patients


Sleep disturbance has been long-standing torments in most of patients with maintenance hemodialysis (HD). In this study, we attempted to explore whether long-term hemoperfusion (HP) could improve sleep disorder and increase overall survival rate in HD patients.

Full Title of Study: “Hemoperfusion in Combination With Hemodialysis for Improvement of Self-reported Sleep Disturbance and Overall Survival Rate in Maintenance Hemodialysis Patients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 1, 2017


  • Device: hemoperfusion(HP)
    • These patients were computer-matched into two groups, involving 100 patients with absolute HD vs. 100 cases with HD+HP.HP was performed 1-2 times/per 2 weeks, and each session lasted for two hours.Self-reported sleep disturbance was evaluated before and after observational time (two-year period), which lasted at least 7 hours based on the recommendations presented by National Institute of Health (NIH). Sleep efficiency (%) was calculated as the ratio of sleep duration to total time in bed, and was multiplied by 100.

Arms, Groups and Cohorts

  • No Intervention: HD(hemodialysis) group
    • HD group as conventional control arm
  • Active Comparator: HD+HP(hemodialysis+hemoperfusion) group
    • HD+HP as active interventional group.HP was performed 1-2 times/per 2 weeks, and each session lasted for two hours.

Clinical Trial Outcome Measures

Primary Measures

  • improvement of self-reported sleep disturbance
    • Time Frame: 2 years
    • Analysis of the sleep disturbance by using Pittsburgh Sleep Quality Index (PSQI) questionnaire

Secondary Measures

  • survival
    • Time Frame: 2 years
    • increase overall survival rate

Participating in This Clinical Trial

Inclusion Criteria

1. duration of maintenance HD should be equal or more than 3 months, 2. patient's age should be equal or more than 18 years Exclusion Criteria:

  • i) he/she diagnosed with malignant tumors, an active rheumatism, infectious diseases, or a severe heart failure ii) he/she would disagree with the study 3. he/she has received a short-term poor prognosis 4. he/she would be more than 80 years old

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Shanghai Pudong Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Jin HM, MD, Professor – Shanghai Pudong Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.